1. Introduction {#sec1-nutrients-10-00068}
===============

Zinc is an essential trace element for living organisms and their biological processes \[[@B1-nutrients-10-00068],[@B2-nutrients-10-00068]\]. The body cannot accumulate zinc and it is, therefore, essential to take this element consistently in the diet. Although dietary zinc levels vary substantially, eukaryotic cells need to maintain intracellular zinc homeostasis to ensure its proper function. This homeostasis is regulated in mammals by import and export processes, vesicle retaining zinc (zincosomes) and association to metallothioneins (MTs) \[[@B3-nutrients-10-00068],[@B4-nutrients-10-00068]\]. Zinc plays a key structural or catalytic role in more than 300 enzymes and is involved at all levels of cellular signal transduction. Zinc is involved in cell communication, cell proliferation, differentiation and survival. Therefore, zinc also plays a key role in regulating the immune system, both innate and adaptive, with consequent implications in pathologies where zinc deficiency and inflammation are observed.

The understanding of zinc's importance in human health unfortunately begun only in the 1960s. Zinc deficiency is associated with a decline in the immune system, with inflammation leading to chronicity \[[@B5-nutrients-10-00068]\]. In addition, dietary zinc deficiency was considered to be very rare, although it affects 20--25% of the world's population \[[@B6-nutrients-10-00068],[@B7-nutrients-10-00068]\]. Data from the World Health Organization \[[@B8-nutrients-10-00068]\] report that zinc deficiency is the fifth largest health risk factor in developing countries and the eleventh in the world \[[@B9-nutrients-10-00068]\]. Rarely is zinc deficiency seen as a serious deficit; more frequently it is seen as a less accentuated deficit. Patients with severe deficits present: lymphopenia, decreased ratio between T helper (Th) to cytotoxic T cells, reduced natural killer (NK) cell activity, and increased monocytes cytotoxicity. This condition characterizes the malabsorption autosomal recessive syndrome, Acrodermatitis enteropathica, due to a mutation of a zinc-importing protein, ZIP4 \[[@B10-nutrients-10-00068]\].

Less accentuated zinc deficiency states can be caused by nutritional deficits due, for example, to a diet high in lignin and phytates, in vegetarians and vegans, chelating zinc, so preventing its proper absorption \[[@B11-nutrients-10-00068],[@B12-nutrients-10-00068]\]. This state is characterized by slight weight loss, rough skin, oligospermia and hyperammoniaemia \[[@B13-nutrients-10-00068]\].

Several clinical trials of zinc supplementation have been conducted in patients with zinc deficit suffering from various pathologies (viral, bacterial and parasitic infections or autoimmune diseases) \[[@B14-nutrients-10-00068]\], or as vaccine supplements \[[@B15-nutrients-10-00068]\]. Although there is countless evidence supporting the fact that controlled zinc supplementation can prevent chronic inflammation and other zinc deficiency-related illnesses, or even improve symptoms (as seen in both humans and animal models), to date zinc supplementation does not fall into commonly used medical practices in risk subjects/populations. The purpose of this study was to examine the experimental evidence reported in the literature over the last 40 years regarding zinc levels in the body of patients with autoimmune disorders compared to control individuals. The biological matrices for which it was possible to collect enough bibliographic material to perform a meta-analysis were predominantly serum and plasma; to a lesser extent data were collected on urine, hair and spinal fluid.

2. Materials and Methods {#sec2-nutrients-10-00068}
========================

2.1. Search Strategy {#sec2dot1-nutrients-10-00068}
--------------------

In order to select the included studies, a literature search was undertaken of PubMed, Cochrane Central Register of Controlled Trials, Web of Science and Science Direct databases from inception to 23 January 2017 and without any limitation of on year of publication. Keywords used were zinc and ((dietary or supplement) or (serum or plasma)) and (autoimmune disease or autoimmunity). Typing, in the search window, the keywords in the databases chosen, without any restrictions, the result was a list of publications for which only the title, authors and abstracts were available. After eliminating the duplicates the titles and abstracts of the remaining articles were read and those not relevant for the purpose of this meta-analysis were excluded. After this step, the entire manuscript of each remaining paper, defined as eligible, was read, thus excluding those that did not fall within the criteria defined in the "study eligibility criteria" ([Section 2.3](#sec2dot3-nutrients-10-00068){ref-type="sec"}, below). Finally, the papers that satisfied all selection criteria have been included in the meta-analysis.

Full search details for all databases are presented in [Table S1 (Supplemental Material)](#app1-nutrients-10-00068){ref-type="app"}. This study was performed according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) requirements \[[@B16-nutrients-10-00068],[@B17-nutrients-10-00068]\]. The standard flowchart, which describes the process selection, is reported in [Figure 1](#nutrients-10-00068-f001){ref-type="fig"}.

2.2. Study Selection {#sec2dot2-nutrients-10-00068}
--------------------

All reference lists were downloaded for elimination of duplicates. Furthermore, title and abstract of each reference were screened by two independent reviewers to perform the eligibility assessment of full text for this review. Study eligibility was restricted to human studies and English language.

2.3. Study Eligibility Criteria {#sec2dot3-nutrients-10-00068}
-------------------------------

Observational studies, prospective and retrospective studies, case-control studies or randomized controlled trials (RCTs) investigating the relationship between zinc status and autoimmune diseases were eligible for inclusion. In particular, only diseases for which the autoimmunity was a franc condition were included in this study. The American Autoimmune Related Diseases Association (AARDA) \[[@B18-nutrients-10-00068]\] was consulted to verify that the diseases considered in this study were really autoimmune diseases.

The studies were selected if zinc concentration in biological samples or dietary/supplemental zinc were an index of zinc status.

Moreover, the presence of both number of subject involved (≥5) and the statistical parameters were taken into account for the meta-analysis process. On the other hand, letters, conference proceedings, reviews, duplicated data, data of both animal and cellular studies, and studies that did not indicate data of interest were excluded. Although studies on animals are not considered eligible for the meta-analysis process, a discussion on them was performed separately. Also, thirteen studies were excluded because we did not have access to the full text, maybe the most of these studies were published more than 20 years ago.

2.4. Study Quality Assessment and Data Extraction {#sec2dot4-nutrients-10-00068}
-------------------------------------------------

The Newcastle-Ottawa Scale (NOS) for case-control studies was used to assess the quality of the included studies \[[@B19-nutrients-10-00068]\]. Ten full-text studies were excluded because control data was not complete in reference to both number of controls and their relationship with cases. Two independent reviewers extracted data from each eligible study. The data extracted included the type of study (observational studies, prospective and retrospective studies, case-control studies, randomized controlled trials), country, year of publication, sample size, age and sex of patients, autoimmune disease, zinc status in biological samples, type of samples, method of samples analysis, statistical method, standard deviation and statistical significance.

[Table 1](#nutrients-10-00068-t001){ref-type="table"} reports the general characteristics of selected studies included in meta-analysis in reference to serum samples whereas [Table 2](#nutrients-10-00068-t002){ref-type="table"} indicates the baseline characteristics for meta-analysis related to plasma samples. Furthermore, [Table 3](#nutrients-10-00068-t003){ref-type="table"} reports the general information about the studies that are related to hair, urine and Cerebral Spinal Fluid (CSF) samples.

In most of the included studies, the measurement unit of the zinc concentration data were different for the same biological media. For this reason, all data of zinc in both serum and plasma samples were converted in μg/mL, whereas zinc data in hair samples were converted in μg/g.

2.5. Statistical Analysis {#sec2dot5-nutrients-10-00068}
-------------------------

Data were processed by MetaEasy Excel add-in (Microsoft Corporation, Redmond, WA, USA), which used seven different methods. In particular, three methods refer to dichotomous data and four methods refer to continuous data. In order to improve their heterogeneity, data were grouped depending on different biological media: serum, plasma, hair, urine and cerebrospinal fluid. Means of zinc status in both patients and controls, standard deviations of zinc status in both patients and controls, number of subjects involved and *p*-value were used. *p*-value \< 0.05 was considered as statistically significant.

Also, overall estimates of effect were performed with seven models: Fixed Effects (FE), DerSimonial-Laird (DL), Q method (Q), Maximum-Likelihood (ML), Profile---Likelihood (PL), *t*-Test (T) and Permutations method (PE). Heterogeneity was assessed by different measures: Cochrane's Q, τ^2^ test, I^2^ test and H^2^M test. Publication bias was evaluated using funnel plot 3 considering the estimate of effects and their standard errors as a precision indicator (1/SE) \[[@B82-nutrients-10-00068]\].

3. Results {#sec3-nutrients-10-00068}
==========

From 26,095 articles identified by literature search, 21,766 duplicates were deleted. After the screening of 4329 remaining articles, 4150 of them were excluded because they were irrelevant for our study. Afterwards, 179 papers were considered potentially relevant for our study but only 62 of them satisfied the inclusion criteria (see [Section 2.4](#sec2dot4-nutrients-10-00068){ref-type="sec"}). Therefore, 117 articles were excluded and the reasons for their exclusion is shown in PRISMA diagram ([Figure 1](#nutrients-10-00068-f001){ref-type="fig"}). In particular, 13 of the 117 papers were excluded because, with the means available to the Italian library system, it was not possible to retrieve them. However, the 13 papers are listed in [Table S2 (Supplemental Material)](#app1-nutrients-10-00068){ref-type="app"}.

3.1. Zn Status and Autoimmune Diseases {#sec3dot1-nutrients-10-00068}
--------------------------------------

The relationship between Zn status and autoimmune diseases has been investigated by many authors since the 1970s. The 62 studies included in the meta-analysis were case-control studies. Also, all of them were published between 1975 and 2017 and they are related to different autoimmune diseases. Indeed, 22 studies describe the zinc status in Type 1 Diabetes (T1D), 18 full-text are related to Rheumatoid Arthritis (RA), 7 articles investigated zinc status in Multiple Sclerosis (MS) patients while 15 papers are related to other diseases among which Alopecia Areata (AA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris (PV), Autoimmune Hepatitis (AH), Celiac Disease (CD), Hashimoto Thyroiditis (HT), Sjogren's syndrome (SS), Juvenile Idiopathic Arthritis (JIA).

3.2. Zn Status in Serum Samples {#sec3dot2-nutrients-10-00068}
-------------------------------

The meta-analysis results show that, for all models, Zn concentration in serum of autoimmune disease patients was significantly lower than controls (FE: mean effect = −1.19 and confidence interval: −1.26 to −1.11; DL: mean effect = −1.29 and confidence interval: −1.91 to −0.67; Q: mean effect = −1.29 and confidence interval: −1.91 to −0.67; ML: mean effect = −1.29 and confidence interval: −1.96 to −0.63; PL: mean effect = −1.29 and confidence interval: −1.97 to −0.61; T: mean effect = −1.29 and confidence interval: −1.99 to −0.60; PE: mean effect = −1.29 and confidence interval: −2.95 to −0.49). Indeed, 70% of the articles considered show that patients have a zinc deficiency compared to the control group.

Regarding the heterogeneity of data, the elaboration shows the following results: Cochrane Q = 2589.53; τ^2^ = 3.88 (for DL model); τ^2^ = 4.52 (for ML and PL models); *I*^2^ = 98.49%; H^2^M = 65.39. Forest plot in [Figure 2](#nutrients-10-00068-f002){ref-type="fig"} shows the study effects for each study and the overall estimates effects. Despite high heterogeneity, overall estimates effects were positive for all models. Moreover, overall effects that were calculated with FE models were more efficient than effects calculated with the other models.

3.3. Zn Status in Plasma Samples {#sec3dot3-nutrients-10-00068}
--------------------------------

As already seen for serum, also in plasma samples the meta-analysis results show that, for all models, Zn concentration in the serum of autoimmune disease patients was significantly lower than controls. Indeed, for 62% of the articles included in the meta-analysis process, patients had lower zinc concentrations than controls.

As shown in [Figure 3](#nutrients-10-00068-f003){ref-type="fig"}, only FE model overall estimates effects could be considered favorable (FE: mean effect = −3.97 and confidence interval: −4.08 to −3.87). Even in this case, as in the previous one, data was highly heterogeneous.

3.4. Zn Status in Hair, Urine and Cerebrospinal Fluid Samples {#sec3dot4-nutrients-10-00068}
-------------------------------------------------------------

In reference to Zn hair concentration, only FE model overall estimates effects could be considered favorable (FE: mean effect = −2.49 and confidence interval: −2.72 to −2.28). However, heterogeneity was considerable and the number of studies was limited. On the other hand, no significant variations in urinary and CSF zinc were observed between patients and controls.

3.5. Publication Bias {#sec3dot5-nutrients-10-00068}
---------------------

To evaluate the presence of publication bias, Funnel Plots were calculated. As shown in [Figure 4](#nutrients-10-00068-f004){ref-type="fig"}, in both meta-analysis related to serum Zn and plasma Zn, it is possible to observe the presence of bias in the selected literature.

4. Discussion {#sec4-nutrients-10-00068}
=============

This review of the literature on the possible linkage between zinc levels (especially in serum and plasma) and autoimmune diseases has revealed a huge amount of studies on this subject, although the selection due to meta-analysis methods has narrowed the final analysis to 62 publications, temporally distributed as shown in [Figure S1 (Supplemental Material)](#app1-nutrients-10-00068){ref-type="app"}.

As expected, the data presented in this review, although very heterogeneous in the manner of collecting and investigating samples, etc., have proved to be extremely consistent in witnessing a deficiency of zinc in serum and plasma of patients compared to controls. A recurring question found in many studies was whether alterations in the homeostasis of this element represent the basis of the inflammatory status or consequences thereof.

As is well known, there are populations such as Finnish or Sardinian with polygenic predisposition to autoimmune diseases, in whom there has been a natural selection in favor of certain genetic loci, playing a role in the immune response. In particular, certain HLA (Humane Leucocyte Antigens) haplotypes, such as HLA-DR3-B18 in Sardinia and HLA-DR4 in Finland, are particularly frequent in those populations, terribly increasing the relative risk of developing multiple sclerosis \[[@B83-nutrients-10-00068]\], type 1 diabetes \[[@B84-nutrients-10-00068]\] and even comorbidity of these two and other autoimmune pathologies \[[@B85-nutrients-10-00068]\]. In addition, recent works have also shown that DNA genetic variations largely drive the development and function of specific leukocyte subsets \[[@B86-nutrients-10-00068]\], in particular those who may have key pro-inflammatory or regulatory roles in autoimmune diseases \[[@B87-nutrients-10-00068]\].

Of note, there is the repeated observation of a sex-related bias in different autoimmune diseases, but often not attributable to known genetic causes \[[@B88-nutrients-10-00068],[@B89-nutrients-10-00068]\], and that environmental influences at various timepoints contribute to a shift towards unbalanced immune responses \[[@B90-nutrients-10-00068],[@B91-nutrients-10-00068]\].

Zinc has been recognized as one of these factors, as its homeostasis is essential against inflammatory diseases to regulate different aspects of the immune system, both for innate and adaptive immune response, cell cycle progression, cell maturation and differentiation \[[@B92-nutrients-10-00068]\]. Zinc deficiency is therefore associated with an incorrect maturation and function of T and B cells, an unbalanced ratio between Th1 and Th2 \[[@B93-nutrients-10-00068]\], and between regulatory and pro-inflammatory T cells, and a weakening of NK cell function. Zinc can inhibit Th17 lymphocytes, which confer susceptibility to autoimmune diseases owing to their strong inflammatory properties, as well as a variety of other proinflammatory responses on T-cells and B-cells \[[@B94-nutrients-10-00068],[@B95-nutrients-10-00068]\].

These unbalanced states can, however, be restored by zinc integration \[[@B96-nutrients-10-00068],[@B97-nutrients-10-00068],[@B98-nutrients-10-00068]\]. As demonstrated in several studies analyzed in this meta-analysis, patients with multiple sclerosis exhibit low levels of zinc in the plasma \[[@B99-nutrients-10-00068],[@B100-nutrients-10-00068],[@B101-nutrients-10-00068]\]. This is also observed in the mouse model, affected by experimental autoimmune encephalomyelitis (EAE), in which the symptoms decrease in severity and even regress after zinc treatment, inducing proliferation of regulatory T cells and decreasing pro-inflammatory cells \[[@B102-nutrients-10-00068],[@B103-nutrients-10-00068],[@B104-nutrients-10-00068],[@B105-nutrients-10-00068]\]. Even in type 1 diabetes, the autoimmune diabetes, zinc homeostasis plays a key role by acting on various molecular mechanisms \[[@B106-nutrients-10-00068],[@B107-nutrients-10-00068]\]. The protagonist in beta-pancreatic cells is definitely the ZnT8 zinc importer, essential for the transport of insulin secretory vesicles, and for the formation of insulin granules \[[@B108-nutrients-10-00068],[@B109-nutrients-10-00068],[@B110-nutrients-10-00068]\]. Even in this case, the benefits of zinc supplementation are known. Chronic zinc deficiency increases inflammation potentially leading to its chronic perpetuation \[[@B5-nutrients-10-00068]\].

Alternatively, hypozincemia could represent a common result of inflammation during the autoimmune disorders here discussed. It has been shown that induction of acute-phase response upregulates Zip14 via IL-6 and IL-1 signaling \[[@B111-nutrients-10-00068]\], inducing liver sequestration and redistribution in the cellular compartment \[[@B112-nutrients-10-00068]\]. Furthermore, the experiments conducted by Bonaventura and colleagues on synovial cells isolated from joints of patients affected by rheumatoid arthritis are illuminating. The authors have shown that exposure of cells to pro-inflammatory cytokines such as interleukin-17 and tumor necrosis factor alpha, increases the expression of zinc importer carriers, resulting in enhanced intracellular Zn uptake and further increasing inflammation and interleukin-6 production. These experiments have clarified the existence of a feedback loop between inflammation and cellular zinc uptake \[[@B113-nutrients-10-00068]\].

Indeed, in pathologies such as multiple sclerosis, serum levels of zinc decrease mainly during relapses; in pathologies characterized by chronic inflammation, such as rheumatoid arthritis, a continuous recruitment of zinc within the cells would be established, hence a continuous depletion of zinc in serum. Probably, in the induction of autoimmunity, there is a role for either a primary zinc deficiency and for its secondary reduction due to inflammation, that warrant further focused studies for a thorough determination of timing (preclinical phase of disease vs. overt disease or during pregnancy, childhood, and elderly), cause/pathophysiology, degree of reduction and span/duration (over time) of hypozincemia. Finally, zinc also acts as a co-factor for many proteins implicated in the epigenome establishment. This means that the development of a new organism may be conditioned, from the earliest stages, by possible imbalance in zinc homeostasis \[[@B114-nutrients-10-00068]\]. Therefore, interventions to correct any nutritional imbalances should be anticipated during the stages of pregnancy and lactation. In fact, zinc deficiencies during pregnancy are associated with fetal or adult illness, also due to the improper development of the immune system \[[@B115-nutrients-10-00068],[@B116-nutrients-10-00068],[@B117-nutrients-10-00068]\].

One aspect not to be overlooked is the bioaccessibility and then the bioavailability of this and other elements. In this regard, environmental studies \[[@B118-nutrients-10-00068],[@B119-nutrients-10-00068]\] are also desirable for helping to clarify the potential environmental impact of exposures/deficiencies to particular elements, essential for/toxic to human health, including any corrective measures to improve the conditions in which man lives and works and therefore having a strong impact on human health. In fact, in the mining exploration field, it is well known that the abundance of some elements is typically linked to some lithologies and/or metallogenic contexts. This relative abundance (or deficiency) affects any media linked to these environments such as water \[[@B119-nutrients-10-00068],[@B120-nutrients-10-00068],[@B121-nutrients-10-00068],[@B122-nutrients-10-00068],[@B123-nutrients-10-00068],[@B124-nutrients-10-00068],[@B125-nutrients-10-00068],[@B126-nutrients-10-00068]\], soil \[[@B89-nutrients-10-00068],[@B118-nutrients-10-00068],[@B119-nutrients-10-00068],[@B124-nutrients-10-00068],[@B127-nutrients-10-00068],[@B128-nutrients-10-00068],[@B129-nutrients-10-00068],[@B130-nutrients-10-00068],[@B131-nutrients-10-00068],[@B132-nutrients-10-00068]\] and so also the biological sphere. However, it should be considered that the complexity and dynamism of the environment could complicate the interpretations \[[@B133-nutrients-10-00068]\].

Given the importance of zinc in regulating the functioning of the immune system, it is, therefore, logical to associate an imbalance in the homeostasis of this element with the state of autoimmunity. It would therefore be desirable to mount a screening campaign for the evaluation of zinc levels in neonatal, preschool and school-age children, and hence a relevant campaign for the integration of essential elements for man, including zinc. In populations at higher genetic risk of autoimmunity it would be therefore interesting to have a clinical trial investigate personalized zinc supplementation for preventing and/or treating autoimmune diseases.
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nutrients-10-00068-t001_Table 1

###### 

Characteristics of selected studies included in meta-analysis in reference to serum samples.

  Authors                                                 Year   Disease   No.     Zn Status (μg/mL)      Direction             
  ------------------------------------------------------- ------ --------- ------- ---------------------- ----------- --------- ----------------------
  Aaseth et al. \[[@B20-nutrients-10-00068]\]             1978   RA        22      12                     0.654       0.850     low zinc in patients
  Abdel Fattah et al. \[[@B21-nutrients-10-00068]\]       2016   AA        50      50                     0.755       0.857     low zinc in patients
  Arreola et al. \[[@B22-nutrients-10-00068]\]            1990   T1D       22      11                     0.734       1.114     low zinc in patients
  Banford et al. \[[@B23-nutrients-10-00068]\]            1982   RA        85      49                     12.100      12.100    no difference
  Bhat et al. \[[@B24-nutrients-10-00068]\]               2009   AA        50      50                     78.000      88.000    low zinc in patients
  Bideci et al. \[[@B25-nutrients-10-00068]\]             2005   T1D       28      15                     0.961       1.231     low zinc in patients
  Brandao-Neto et al. \[[@B26-nutrients-10-00068]\]       1999   T1D       10      10                     1.040       1.020     no difference
  Car et al. \[[@B27-nutrients-10-00068]\]                1992   T1D       15      15                     0.562       0.772     low zinc in patients
  Dijkmans et al. \[[@B28-nutrients-10-00068]\]           1987   RA        25      18                     0.667       0.942     low zinc in patients
  Dore-Duffy et al. \[[@B29-nutrients-10-00068]\]         1983   MS        63      62                     831.000     817.000   no difference
  Dore-Duffyet al. \[[@B30-nutrients-10-00068]\]          1990   RA        57      18                     0.850       0.997     low zinc in patients
  Erdal et al. \[[@B31-nutrients-10-00068]\]              2008   HT        43      49                     1.093       1.015     no difference
  Ghazavi et al. \[[@B32-nutrients-10-00068]\]            2012   MS        60      60                     0.402       1.278     low zinc in patients
  Hagglof et al. \[[@B33-nutrients-10-00068]\]            1983   T1D       66      79                     0.915       1.000     low zinc in patients
  Hansson et al. \[[@B34-nutrients-10-00068]\]            1975   RA        37      70                     1.066       1.055     low zinc in patients
  42                                                      26     1.052     0.965   low zinc in patients                         
  Haugen et al. \[[@B35-nutrients-10-00068]\]             1992   JIA       8       17                     0.909       0.981     low zinc in patients
  Helgeland et al. \[[@B36-nutrients-10-00068]\]          2000   JIA       14      22                     0.830       0.870     low zinc in patients
  Helliwell et al. \[[@B37-nutrients-10-00068]\]          1984   RA        50      50                     0.804       0.883     low zinc in patients
  Isbir et al. \[[@B38-nutrients-10-00068]\]              1994   T1D       20      20                     0.565       0.696     low zinc in patients
  Jansen et al. \[[@B39-nutrients-10-00068]\]             2012   T1D       8       8                      0.768       0.883     low zinc in patients
  Javanbakht et al. \[[@B40-nutrients-10-00068]\]         2012   PV        43      58                     0.906       0.988     no difference
  Kapaki et al. \[[@B41-nutrients-10-00068]\]             1989   MS        15      28                     1.030       1.100     no difference
  Kiilerich et al. \[[@B42-nutrients-10-00068]\]          1986   T1D       7       12                     0.798       0.948     low zinc in patients
  Kiilerich et al. \[[@B43-nutrients-10-00068]\]          1990   T1D       10      104                    1.007       0.948     no difference
  Kobbah et al. \[[@B44-nutrients-10-00068]\]             1988   T1D       30      44                     0.785       0.909     low zinc in patients
  Lin et al. \[[@B45-nutrients-10-00068]\]                2016   T1D       88      76                     0.910       0.940     no difference
  Iyanda et al. \[[@B46-nutrients-10-00068]\]             2011   AA        20      20                     0.792       0.933     low zinc in patients
  20                                                      20     0.782     0.933   low zinc in patients                         
  Maldonado et al. \[[@B47-nutrients-10-00068]\]          1991   T1D       22      22                     1.111       1.197     no difference
  Mierzecki et al. \[[@B48-nutrients-10-00068]\]          2011   RA        74      30                     0.801       0.720     low zinc in patients
  Negoro et al. \[[@B49-nutrients-10-00068]\]             2004   SS        31      15                     0.706       0.866     low zinc in patients
  Nicoloff et al. \[[@B50-nutrients-10-00068]\]           2005   T1D       35      20                     0.675       1.268     low zinc in patients
  Onal et al. \[[@B51-nutrients-10-00068]\]               2011   RA        32      52                     0.430       0.748     low zinc in patients
  Palm et al. \[[@B52-nutrients-10-00068]\]               1982   MS        21      21                     0.850       0.968     low zinc in patients
  29                                                      29     0.791     0.863   low zinc in patients                         
  Raz et al. \[[@B53-nutrients-10-00068]\]                1989   T1D       23      22                     0.928       0.170     low zinc in patients
  Sahebari et al. \[[@B54-nutrients-10-00068]\]           2014   SLE       123     100                    0.701       0.860     low zinc in patients
  Silverio Amancio et al. \[[@B55-nutrients-10-00068]\]   2003   JIA       20      10                     0.897       0.900     no difference
  21                                                      13     0.976     0.950   no difference                                
  Ullah et al. \[[@B56-nutrients-10-00068]\]              2017   RA        61      61                     0.856       0.959     low zinc in patients
  Yazdanpanah et al. \[[@B57-nutrients-10-00068]\]        2011   PV        25      25                     0.770       1.207     low zinc in patients
  Yilmaz et al. \[[@B58-nutrients-10-00068]\]             2005   SLE       27      20                     0.875       0.990     low zinc in patients
  Zoli et al. \[[@B59-nutrients-10-00068]\]               1998   RA        57      20                     85.600      108.100   low zinc in patients

Abbreviations: AA, Alopecia Areata; HT, Hashimoto Thyroiditis; JIA, Juvenile Idiopathic Arthritis; MS, Multiple Sclerosis; PV, Pemphigus Vulgaris; RA, Rheumatoid Arthritis; SLE, Systemic Lupus Erythematosus; SS, Sjogren's Syndrome; T1D, Type 1 Diabetes.

nutrients-10-00068-t002_Table 2

###### 

Characteristics of selected studies included in meta-analysis in reference to plasma samples.

  Authors                                            Year   Disease   No.     Zn Status (μg/mL)   Direction                        
  -------------------------------------------------- ------ --------- ------- ------------------- ---------------------- --------- -----------------------
  Arreola et al. \[[@B60-nutrients-10-00068]\]       1986   T1D       9       12                  73.490                 112.460   low zinc in patients
  Bacon et al. \[[@B61-nutrients-10-00068]\]         1990   JIA       8       9                   0.805                  0.983     low zinc in patients
  JIA                                                14     9         0.859   0.983               low zinc in patients             
  JIA                                                12     9         0.875   0.983               low zinc in patients             
  Balogh et al. \[[@B62-nutrients-10-00068]\]        1980   RA        140     100                 11.740                 15.100    low zinc in patients
  Crofton et al. \[[@B63-nutrients-10-00068]\]       1983   CD        12      15                  0.582                  0.974     low zinc in patients
  CD                                                 10     15        0.628   0.974               low zinc in patients             
  Cunningham et al. \[[@B64-nutrients-10-00068]\]    1994   T1D       14      15                  0.950                  0.910     no difference
  Dore-Duffy et al. \[[@B29-nutrients-10-00068]\]    1983   MS        68      60                  845.000                788.000   low zinc in patients
  Dore-Duffy et al. \[[@B30-nutrients-10-00068]\]    1990   RA        57      17                  0.795                  0.890     low zinc in patients
  Ho et al. \[[@B65-nutrients-10-00068]\]            1986   MS        45      23                  0.890                  0.880     high zinc in patients
  Kennedy et al. \[[@B66-nutrients-10-00068]\]       1975   RA        113     100                 0.857                  0.990     low zinc in patients
  Melchior et al. \[[@B67-nutrients-10-00068]\]      1989   T1D       14      36                  0.947                  0.943     no difference
  T1D                                                12     36        0.879   0.817               no difference                    
  Milanino et al. \[[@B68-nutrients-10-00068]\]      1993   RA        120     70                  0.895                  1.019     low zinc in patients
  RA                                                 10               0.526   0.106               low zinc in patients             
  Mocchegiani et al. \[[@B69-nutrients-10-00068]\]   1989   T1D       15      16                  0.793                  1.064     low zinc in patients
  Naveh et al. \[[@B70-nutrients-10-00068]\]         1997   RA        13      8                   0.590                  1.110     low zinc in patients
  RA                                                 16     8         0.600   1.110               low zinc in patients             
  Pereira et al. \[[@B71-nutrients-10-00068]\]       2011   AH        23      25                  0.719                  0.807     low zinc in patients
  Quilliot et al. \[[@B72-nutrients-10-00068]\]      2001   T1D       25      20                  0.940                  0.970     low zinc in patients
  Rohn et al. \[[@B73-nutrients-10-00068]\]          1993   T1D       45      12                  0.942                  0.981     no difference
  Ruiz et al. \[[@B74-nutrients-10-00068]\]          1998   T1D       16      9                   1.020                  1.079     no difference
  T1D                                                13     7         1.046   1.059               no difference                    
  T1D                                                31     19        1.020   1.040               no difference                    
  T1D                                                34     24        1.046   1.040               no difference                    
  T1D                                                31     17        1.033   1.046               no difference                    
  T1D                                                25     14        1.013   1.059               no difference                    
  Smith et al. \[[@B75-nutrients-10-00068]\]         1989   MS        27      33                  0.987                  1.000     no difference
  Tuncer et al. \[[@B76-nutrients-10-00068]\]        1999   RA        38      20                  1.087                  1.253     low zinc in patients
  Viktorinova et al. \[[@B77-nutrients-10-00068]\]   2009   T1D       11      34                  0.885                  0.942     no difference
  Yazar et al. \[[@B78-nutrients-10-00068]\]         2005   RA        25      25                  0.663                  0.658     no difference

Abbreviations: AH, Autoimmune Hepatitis; Cd, Celiac Disease; JIA, Juvenile Idiopathic Arthritis; MS, Multiple Sclerosis; RA, Rheumatoid Arthritis; T1D, Type 1 Diabetes.
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###### 

Characteristics of selected studies included in meta-analysis in reference to hair, urine and CSF samples.

  Authors                                          Year   Disease   No.      Biological Sample      Zn Status (μg/g)        Direction            
  ------------------------------------------------ ------ --------- -------- ---------------------- ----------------------- ----------- -------- -----------------------
  Afridi et al. \[[@B79-nutrients-10-00068]\]      2015   RA        15       14                     Hair                    122.00      178.00   low zinc in patients
  15                                               12     117.00    167.00   low zinc in patients                                                
  12                                               13     135.00    203.00   low zinc in patients                                                
  11                                               13     126.00    203.00   low zinc in patients                                                
  Afridi et al. \[[@B80-nutrients-10-00068]\]      2012   RA        39       47                     Hair                    112.00      225.00   low zinc in patients
  34                                               52     138.00    250.00   low zinc in patients                                                
  23                                               22     122.00    178.00   low zinc in patients                                                
  20                                               19     135.00    203.00   low zinc in patients                                                
  Hagglof et al. \[[@B33-nutrients-10-00068]\]     1983   T1D       74       30                     Hair                    160.90      190.80   low zinc in patients
  Mierzecki et al. \[[@B48-nutrients-10-00068]\]   2011   RA        71       75                     Hair                    150.37      150.37   no difference
  Kiilerich et al. \[[@B43-nutrients-10-00068]\]   1990   T1D       10       28                     Urine                   1006.85     509.96   high zinc in patients
  Milanino et al. \[[@B68-nutrients-10-00068]\]    1993   RA        75       50                     Urine                   437.9       457.50   no difference
  Maldonado et al. \[[@B47-nutrients-10-00068]\]   1991   T1D       13       8                      Urine                   353         984.00   low zinc in patients
  Naveh et al. \[[@B70-nutrients-10-00068]\]       1997   RA        16       8                      Urine                   538         984.00   low zinc in patients
  22                                               22     Urine     1396     611.00                 high zinc in patients                        
  Kapaki et al. \[[@B41-nutrients-10-00068]\]      1989   MS        15       28                     CSF                     34.73       34.70    no difference
  Melo et al. \[[@B81-nutrients-10-00068]\]        2003   MS        18       19                     CSF                     19.00       23.50    no difference

Abbreviations: MS, Multiple Sclerosis; RA, Rheumatoid Arthritis, T1D, Type 1 Diabetes.
